A major meta-analysis pooling 50 studies, including 19 randomized controlled trials and 31 cohort studies with 28,292 coronary artery disease patients, tests drug-coated balloons (DCBs) against standard percutaneous coronary intervention options like drug-eluting stents (DES), bare-metal stents (BMS), and plain old balloon angioplasty (POBA) in de novo lesions—those never treated before. 
Unlike their proven role in fixing in-stent restenosis, DCBs' place in fresh blockages remained unclear until now. In the study published in the Cardiovascular Therapeutics, the researchers extracted the studies from the PubMed, Embase, Web of Science, and Cochrane up to November 2024, focusing on major adverse cardiac events (MACE) like heart attacks, deaths, or repeat procedures, plus late lumen loss (LLL), a direct measure of artery re-narrowing. Trial sequential analysis added rigor to judge if results hold water.
DCBs Beat Non-Drug Options on Events and Narrowing
DCBs cut MACE risk by nearly half against noncoated devices like BMS or POBA (RR=0.52, 95% CI: 0.40–0.69), showing clear wins in safety and event rates for new lesions. They also slashed LLL far more than all controls combined (MD=−0.22, 95% CI: −0.29 to −0.14), meaning treated arteries stayed wider open longer. Interventional cardiologists will value this, as less re-narrowing often means fewer urgent calls back to the cath lab for patients with virgin plaque sites.
Head-to-Head with Stents Shows Near Parity
Against DES, the gold standard, DCBs tied on MACE with no edge (RR=0.96, 95% CI: 0.84–1.10), proving comparable real-world safety without leaving metal behind—a big plus for small vessels or future bypass needs. Subgroups held firm across ethnicities, diabetes status, and dual antiplatelet therapy lengths, with DCBs shining extra in small vessels and shorter DAPT scenarios. This flexibility appeals to doctors balancing bleeding risks or treating complex anatomies where stents might bunch up.
Analysis Strengthens LLL Edge, MACE Needs More
Trial sequential analysis backed the LLL advantage as firm, but flagged RCT MACE data as inconclusive, urging bigger trials with modern DCBs and DES generations. Cohort studies bolstered findings, yet long-term follow-up beyond typical trial windows remains a gap. Physicians gain confidence knowing DCBs avoid chronic stent issues like thrombosis while matching event rates.
Real Change for Cath Lab Choices
These results position DCBs as a legit DES alternative for de novo disease, especially where leave-nothing-behind matters. Practices can now weigh vessel size, patient risks, and DAPT tolerance more precisely, potentially cutting costs and complications. As newer tech rolls out, studies must track years-long outcomes to lock in guidelines.